Chinese API maker Yinghua hit with FDA warning letter

FDA China
The company was placed on the FDA’s import alert list in February. (

Chinese API maker Yinghua Biochemical and Pharmaceutical Co. was issued a warning letter by the FDA for data integrity issues and problems with its quality unit.

The agency said in a letter posted to its website that an inspection last October of its facility located in Nankou Industrial Park, Lijiang, Yunnan, China, uncovered repeat manufacturing issues that resulted from an inspection in 2015.

“Our current inspection identified multiple failures to implement your specific corrective actions,” the agency said. “These repeated failures demonstrate that your facility’s oversight and control over the manufacture of drug products is inadequate.” 


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

In the most recent inspection, the company was warned about data integrity questions and for allowing its quality unit to approve the certificate of analysis (COA) to release an API batch to a customer before testing was complete and available for review.

As a result of the inspection, the company was placed on the FDA’s import alert list in February.

The firm was also cited for lacking security controls to access its computer systems, specifically its high-performance chromatography (HPLC) and gas chromatography systems. Each of those systems had only a single username with administrator rights. That could allow any user to delete or modify files without being traced.

Suggested Articles

Having only just completed an expansion in Illinois, PCI Pharma Services will now expand its solid dose facility in Wales in the U.K.

The FDA has come down on a small U.S. drugmaker for taking a skin medication to market even though there were out-of-spec test results at release.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.